Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Dare Bioscience Inc (NASDAQ: DARE) is a clinical-stage biopharmaceutical leader advancing innovative therapies for women’s reproductive and sexual health. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical trial progress, regulatory milestones, and strategic partnerships.
Track the latest developments across DARE’s pipeline of non-hormonal contraceptives, sexual health treatments, and cervical health solutions. Our curated news collection includes updates on FDA submissions, trial results for candidates like Ovaprene® and Sildenafil Cream 3.6%, and collaborations advancing women’s healthcare innovation.
Key focus areas include progress toward addressing unmet needs in bacterial vaginosis treatment, female sexual arousal disorder (FSAD), and HPV-related cervical conditions. Bookmark this page for real-time access to earnings announcements, research publications, and licensing agreements that shape DARE’s position in the biopharma sector.
Daré Bioscience (NASDAQ: DARE) announced the completion of patient recruitment for its Phase 1 clinical trial of DARE-HRT1, an intravaginal ring designed to deliver bio-identical hormones for menopause treatment. The trial aims to assess pharmacokinetics and safety in approximately 30 post-menopausal women. Topline data is expected in Q2 2021. This study could position DARE-HRT1 as a first-in-category product, offering a novel option for hormone therapy. The company plans to utilize existing safety data for regulatory approval through the FDA’s 505(b)(2) pathway.
Daré Bioscience announced that CEO Sabrina Martucci Johnson will participate in two virtual conferences: the M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference on March 17-18, 2021, with presentations available on-demand, and BIO-Europe Spring Digital from March 22-25, 2021. Following the M Vest conference, a webcast will be accessible for two weeks via the company's investor relations website.
Daré focuses on innovative women's health products, including unique therapies for contraception and sexual health.
Daré Bioscience, Inc. (NASDAQ: DARE) announces that President and CEO Sabrina Martucci Johnson will participate in a panel on 'Women’s Health Companies Blazing the Trail' at the 33rd Annual Roth Conference from March 15-17, 2021. The panel discussion will highlight innovations in women's health. A webcast will be available on March 15, 2021, at 5:00 PM ET on their website, remaining accessible until March 29, 2021. Daré focuses on developing therapies for contraception, vaginal health, sexual health, and fertility.
Daré Bioscience, a leader in women's health innovation, will have its CEO, Sabrina Martucci Johnson, present at the H.C. Wainwright Global Life Sciences Conference from March 9 to 10, 2021. The presentation will be accessible starting March 9, 2021, at 7:00 AM EST on the company's website. Daré Bioscience focuses on developing innovative therapies for women's health, including products for contraception, sexual health, and hormone replacement therapy. Key candidates in their pipeline include Ovaprene and Sildenafil Cream for female sexual arousal disorder.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will join a panel at the Maxim Group's Late Stage Innovations in Women’s Health event on March 4, 2021, at 11:00 am ET. The discussion will be moderated by Jason McCarthy, PhD, from Maxim Group. The event aims to highlight advancements in women's health innovation. Daré focuses on developing products that enhance women's health, with multiple candidates in its pipeline, including Ovaprene® and Sildenafil Cream, 3.6%.
Daré Bioscience (NASDAQ: DARE) announced that CEO Sabrina Martucci Johnson will participate in a live panel discussion titled The Evolution of Birth Control on February 23, 2021, at 12:30 p.m. EST during the Women’s Health Innovation Series: Contraception Innovation Summit. The discussion will explore innovation challenges in birth control. Ms. Johnson will highlight Daré's commitment to women's health and the development of three innovative contraceptive candidates: Ovaprene®, DARE-LARC1, and ORB formulations. This virtual summit aims to enhance women's contraceptive experiences, featuring stakeholders from various sectors.
Daré Bioscience, a leader in women’s health, announced that CEO Sabrina Martucci Johnson will present at the BIO CEO & Investor Digital Conference from February 16-18, 2021. The presentation will cover innovative developments in women's health, including Daré's unique product portfolio.
Following the event, a recording will be available on Daré's investor relations website until March 4, 2021. The company focuses on developing differentiated therapies in contraception, vaginal health, sexual health, and fertility.
Daré Bioscience, a leader in women’s health innovation, announced that its CEO, Sabrina Martucci Johnson, will join a fireside chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference from January 11-14, 2021. The chat will be available on-demand starting January 11, 2021, at 6:00 AM ET on the company's website and will remain accessible until January 25, 2021. Daré focuses on advancing innovative therapies for women's health, offering products like Ovaprene, Sildenafil Cream, DARE-BV1, and DARE-HRT1.
Daré Bioscience has announced that its investigational treatment, DARE-BV1, has successfully met its primary and secondary endpoints in a Phase 3 trial for bacterial vaginosis, achieving significant clinical cure rates over placebo. The study involved 307 women, demonstrating a 70.2% cure rate at 21-30 days. The treatment has received Fast Track and QIDP designations from the FDA, with a New Drug Application (NDA) submission planned for the first half of 2021. These results indicate a promising new front-line option for women suffering from bacterial vaginosis.
Daré Bioscience (NASDAQ: DARE) reported its third-quarter financial results for 2020, highlighting significant advances in its product pipeline amid a challenging environment. The company is on track to complete the DARE-BVFREE pivotal study for bacterial vaginosis and anticipates FDA submission in the first half of 2021 if results are favorable. Total expenses increased, with R&D costs rising to approximately $6.2 million due to ongoing projects like DARE-BV1 and Ovaprene. Cash and equivalents stand at $5.4 million, with recent capital raised of about $4.5 million post-quarter.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
